Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

Blood

Volumn 111, Issue 6, 2008, Pages 3116-3125

  Ahonen, Cory L ^a,b   Wasiuk, Anna ^a,b   Fuse, Shinichiro ^a   Turk, Mary Jo ^a,b   Ernstoff, Marc S ^c   Suriawinata, Arief A ^c   Gorham, James D ^a   Kedl, Ross M ^d   Usherwood, Edward J ^a   Noelle, Randolph J ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; CD40 ANTIBODY; FGK 45; IMMUNOLOGICAL ADJUVANT; LIGAND; PHOSPHATE BUFFERED SALINE; S 27609; SERYLISOLEUCYLTYROSYLASPARTYLPHENYLALANYLPHENYLALANYLVALYLTRYPTOPHYLLEUCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; CD40 ANTIGEN; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; LIVER TOXICITY; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL TRANSPLANTATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; INJURY; LIVER; LUNG; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL TRANSPLANTATION; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; LIVER; LUNG; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; TOLL-LIKE RECEPTOR 7;

EID: 42449147062     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-114371     Document Type: Article

References (45)

1. CpG 7909: PF 3512676, PF-3512676. Drugs R D. 2006;7:312-316.
2. Vonderheide RH, Flaherty KT. Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007; 25:876-883.
3. Younes A. CD40 ligand therapy of lymphoma patients. J Clin Oncol. 2001;19:4351-4353.
4. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19: 3280-3287.
5. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
6. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol. 2003;15:396-401.
7. Heath WR, Belz GT, Behrens GM, et al. Crosspresentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev. 2004;199:9-26.
8. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type 1IFN. J Exp Med. 2004;199:775-784.
9. Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol. 2007;178:1564-1572.
10. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 2006;27:49-55.
11. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol. 2002;32: 3235-3245.
12. Kochling J, Konig-Merediz SA, Stripecke R, et al. Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin Cancer Res. 2003;9:3142-3149.
13. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746.
14. Berner V, Liu H, Zhou Q, et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13:354-360.
15. Bartholdy C, Kauffmann SO, Christensen JP, Thomsen AR. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol. 2007;178:1662-1670.
16. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A. 2001;98:10811-10816.
17. McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumorspecific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol. 2006;177:155-161.
18. Betts MR, Brenchley JM, Price DA. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78.
19. Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J lmrnunother (1997). 2005;28:396-402.
20. Rubio V, StugeTB, Singh N. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003:9:1377-1382.
21. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-1198.
22. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CDS T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A. 2004:101:16004-16009.
23. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006: 116:1935-1945.
24. Zhou F, Ajuebor MN, Beck PL, Le T, Hogaboam CM, Swain MG. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology. 2005:42:372-380.
25. Kimura K, Moriwaki H, Nagaki M, et al. Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006; 168:786-795.
26. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigenpresenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol. 2002; 169:5188-5195.
27. Schmitz V, Dombrowski F, Prieto J, et al. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology. 2006; 44:430-439.
28. Pure E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol. 2005;6:1207-1210.
29. Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukoc Biol. 2006;80:1084-1102.
30. Fay JW, PaluckaAK, Paczesny S, et al. Longterm outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006;55:1209-1218.
31. Lesimple T, Neidhard EM, Vignard V, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res. 2006;12:7380-7388.
32. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24:5060-5069.
33. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17:275-281.
34. Erickson LD, Durell BG, Vogel LA, et al. CD40 agonists short circuit humoral immunity. J Clin Invest. 2002; 109:613-620.
35. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083-1088.
36. Geldart TR, Harvey M, Carr N, Glennie M, Johnson P. Gancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: evidence of preclinical efficacy [abstract]. J Clin Oncol. 2004;22: 2577.
37. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs. 2007;67:333-350.
38. Kelley SK, Gelzleichter T, Xie D.et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol. 2006; 148:1116-1123.
39. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med. 2000;6:673-679.
40. French RR, Chan HT, TuttAL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5:548-553.
41. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780-787.
42. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20: 709-760.
43. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Tolllike receptor agonists and antagonists. Nat Med. 2007;13:552-559.
44. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol. 2007;25: 825-826.
45. Uno T Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006;12:693-698.